Navigation Links
ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
Date:3/14/2010

ATLANTA, Georgia, March 14, 2010 /PRNewswire/ -- Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower). This is achieved by adding fenofibrate to simvastatin. Only 20 of these patients need to be treated for 5 years to prevent one cardiovascular event.

To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/r3i/42622/

In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial, published on-line in the New England Journal of Medicine,(1) the group with atherogenic dyslipidemia had 70 percent more cardiovascular events (cardiovascular death, heart attacks and strokes) than patients without. In fact, the risk associated with atherogenic dyslipidemia was comparable to that in people with previous cardiovascular disease (17.3 percent versus 18.1 percent).


'/>"/>
SOURCE Residual Risk Reduction initiative (R3i)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... Company at the Maxim Group Growth Conference at,2:30 p.m. ... being held at the,Grand Hyatt Hotel in New York., ... is available at, http://www.wsw.com/webcast/maxim/oncy/ on the company,s website ...
... Engineering and Operations Appointed -, CLINTON, N.J., ... appointment of Michael Kennedy as Senior Vice President,Engineering ... responsible for,drug-device technology strategy and development., "Michael,s ... critical care as we continue to advance our ...
... Oct. 2 ,ImpediMed Ltd, a pioneer in ... Inc., a global leader in science-based,nutraceutical products, ... announced an agreement to distribute ImpediMed technology,in ... affiliate, Health,World, Ltd, has been a long-standing ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference 2Ikaria Strengthens Executive Leadership Team 2ImpediMed and Metagenics Announce Agreement 2
(Date:7/24/2014)... TORONTO, June 24, 2014 Some sticky research out ... fight against a certain species of toxic grass fungus: ... this month,s Biology Letters , "Ungulate saliva inhibits ... when applied to red fescue grass (which hosts a ... results in slower fungus growth and less toxicity. , ...
(Date:7/24/2014)... Iyer, O.D., a low vision specialist at The University ... School, has been awarded a grant to help Harris ... eyeglasses, medication or surgery. , Even with corrective lenses, ... best. However, there are a variety of low vision ... help offset their vision loss. , Iyer is using ...
(Date:7/24/2014)... fire hazard in the United States, wildland managers often ... and suppressed trees (ladder fuels). These cuttings and ... low fire danger in order to dispose of the ... pollutants, managers often cover all or part of the ... as agricultural plastic, in order to keep water out. ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... and a half acres of Appalachia have been strip-mined, whole ... and communities devastated. Not exactly a promising place for a ... For his startling and bold proposal to clean-up this ... of Appalachia, John Todd, a research professor in the Rubenstein ...
... drug reverses the brain dysfunction inflicted by a genetic ... of TSC patients also suffer from autism, the findings ... autism. Nature Medicine publishes the findings ... mouse model for TSC, the scientists tested rapamycin, a ...
... the Smithsonian,s National Zoo detected a secondary rise in ... Mei Xiang (may-SHONG) earlier this month. The results from ... believe the hormone rise indicates that it would be ... to a cub or comes to the end of ...
Cached Biology News:Buckminster Fuller takes on big coal 2Buckminster Fuller takes on big coal 3Drug reverses mental retardation caused by genetic disorder 2
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: